TransCelerate BioPharma Inc.
A TransCelerate BioPharma Inc. is a non-profit organization with a mission is to collaborate across the global biopharmaceutical research and development.
- Contex:
- It can produce a Clinical Template Suite (CTS).
- It can have website: https://www.transceleratebiopharmainc.com
- ...
- Example(s):
- Counter-Example(s):
- See: Decentralized Autonomous Organization (DAO), Decentralized Clinical Trial, Decentralized Networking System, Decentralized Application (DApp).
References
2022
- https://linkedin.com/company/transcelerate-biopharma-inc-/
- QUOTE: TransCelerate BioPharma Inc. was launched in 2012 as a non-profit organization to improve the health of people around the world by accelerating and enhancing the research and development of innovative new therapies.
Our mission is to collaborate across the global biopharmaceutical research and development community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of new medicines.
Our membership is made up of 20+ of the world’s most innovative and successful biopharmaceutical organizations who provide their best talent to collaborate and develop solutions to overcome industry inefficiencies.
Our growing portfolio of Initiatives develops practical solutions to overcome inefficiencies in clinical trials and is drawn from the combined expertise of our members, and working collaboratively with health authorities, industry groups, research organizations and academia.
- QUOTE: TransCelerate BioPharma Inc. was launched in 2012 as a non-profit organization to improve the health of people around the world by accelerating and enhancing the research and development of innovative new therapies.
2021
- (TransCelerate B. Inc., 2021) ⇒ https://www.transceleratebiopharmainc.com/our-mission/ Retrieved: 2021-10-2.
- QUOTE: TransCelerate BioPharma’s mission is to collaborate across the global biopharmaceutical research and development community to identify, prioritize, design, and facilitate the implementation of solutions designed to drive the efficient, effective and high-quality delivery of new medicines.
2020
- (Parab et al., 2020) ⇒ Abhijit A. Parab, Prasann Mehta, Arundhati Vattikola, Christine K. Denney, Michele Cherry, Rakesh M. Maniar, and Jesper Kjaer. (2020). “Accelerating the Adoption of ESource in Clinical Research: A Transcelerate Point of View.” Therapeutic innovation & regulatory science 54, no. 5
- QUOTE: Proposed solution Industry forums (e.g., TransCelerate, SCDM, eClinical Forum, IMI, and Drug Information Association [DIA]) should collaborate to develop guidelines, tools, standards, eSource adoption templates, data collection methodologies, and best practices for successful eSource end-to-end adoption. They should also engage global regulators and solicit their feedback on these deliverables, working towards developing Global Regulatory Guidance for eSource Implementations. The goal is to ensure that we are collecting the right data in the right way (or the most efficient way) with sufficient precision.
2014
- (Gill, 2014) ⇒ Dalvir Gill. (2014). “Re-inventing Clinical Trials through TransCelerate.” Nature Reviews Drug Discovery, 13(11).
- ABSTRACT: TransCelerate BioPharma was formed in 2012 as a non-profit organization with a mission to collaborate across the biopharmaceutical research and development community to identify, prioritize, design and facilitate the implementation of solutions to drive efficient, effective and high-quality delivery of new medicines.
- INTRODUCTION: TransCelerate BioPharma evolved from discussions at various forums where research and development (R&D) leaders debate current issues facing the biopharmaceutical industry and examine solutions for common challenges. As an objective, non-profit entity, we have brought together a broad coalition of partners, now including 19 biopharmaceutical companies (see the Acknowledgements), also working closely with regulatory bodies including the US Food and Drug Administration (FDA), the European Medicines Agency, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) and Health Canada, as well as organizations such as the Critical Path Institute (C-Path) and the Innovative Medicines Initiative (IMI). Our next step — negotiating a path forward for such a diverse group — required the creation of a plan that would enable us to maintain our focus on identifying and capturing industry-wide efficiencies that would benefit a wide array of stakeholders, including investigators and patients.